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BACKGROUND: Degenerative aortic valve (AoV) disease and resulting aortic stenosis are major clinical health problems. Murine 
models of valve disease are rare, resulting in a translational knowledge gap on underlying mechanisms, functional conse-
quences, and potential therapies. Naïve New Zealand obese (NZO) mice were recently found to have a dramatic decline of left 
ventricular (LV) function at early age. Therefore, we aimed to identify the underlying cause of reduced LV function in NZO mice.
METHODS AND RESULTS: Cardiac function and pulmonary hemodynamics of NZO and age- matched C57BL/6J mice were 
monitored by serial echocardiographic examinations. AoVs in NZO mice demonstrated extensive thickening, asymmetric aor-
tic leaflet formation, and cartilaginous transformation of the valvular stroma. Doppler echocardiography of the aorta revealed 
increased peak velocity profiles, holodiastolic flow reversal, and dilatation of the ascending aorta, consistent with aortic steno-
sis and regurgitation. Compensated LV hypertrophy deteriorated to decompensated LV failure and remodeling, as indicated 
by increased LV mass, interstitial fibrosis, and inflammatory cell infiltration. Elevated LV pressures in NZO mice were associ-
ated with lung congestion and cor pulmonale, evident as right ventricular dilatation, decreased right ventricular function, and 
increased mean right ventricular systolic pressure, indicative for the development of pulmonary hypertension and ultimately 
right ventricular failure.
CONCLUSIONS: NZO mice demonstrate as a novel murine model to spontaneously develop degenerative AoV disease, aortic 
stenosis, and the associated end organ damages of both ventricles and the lung. Closely mimicking the clinical scenario of 
degenerative AoV disease, the model may facilitate a better mechanistic understanding and testing of novel treatment strate-
gies in degenerative AoV disease.
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Among cardiovascular diseases, aortic stenosis (AS) is the most common primary valve disease, with a growing prevalence in the aging popula-
tion.1 In patients aged ≥75 years, the prevalence of AS 
is 2.8%, making AS a main cause of cardiovascular 
morbidity and mortality, independent of the underlying 
cause.2– 4 Apart from congenital cardiac malformations, 
like bicuspid aortic valves (AoVs), gradually progressive 
degenerative AoV disease (DAVD) is the most frequent 
cause for AS in the Western world.5,6 Morphological 
hallmarks of degenerative AoVs include matrix remod-
eling, endothelial dysfunction, lipid deposition, inflam-
matory cell infiltration, and finally severe calcification 
of the valvular stroma, causing a pathophysiologic 
continuum ranging from mild valve thickening without 
relevant hemodynamic changes to impaired leaflet 
motion.7 The latter results in a progressive increase in 
left ventricular (LV) afterload that is initially matched by 
LV hypertrophy to maintain cardiac output. However, 
as the disease advances chronically, elevated LV 
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end- diastolic pressure ultimately results in LV dilatation 
and failure.8 Subsequent secondary pulmonary hyper-
tension (PH) and ultimately right ventricular (RV) failure 
present frequent and serious complications with poor 
clinical outcome in patients with severe AS.9,10 This 
fatal progression of DAVD is orchestrated by multiple 
risk factors, including male sex, age, obesity, and dys-
lipidemia, further accelerating the disease process.11– 14
Although this pathophysiological sequence is well 
characterized, the underlying mechanisms of DAVD re-
main poorly understood, at least in part because of the 
lack of appropriate preclinical animal models. Despite 
the high clinical prevalence of AS, murine models of 
valve diseases are rare, often based on complex inter-
vention strategies, and commonly lack significant he-
modynamic stenosis that is critical for the development 
of the clinical phenotype.15– 18 Today, surgical interven-
tion remains the only option to treat AS through valve 
replacement or transcatheter AoV implantation, high-
lighting the unmet clinical need for developing drug 
target- based therapeutic strategies for the treatment 
or prevention of DAVD and AS.19
The New Zealand obese (NZO) mouse is an estab-
lished polygenic model for metabolic syndrome and 
type 2 diabetes.20 When fed a high- fat diet, these mice 
become morbidly obese, with associated hypertension, 
hyperinsulinemia, and hypercholesterolemia.21 Recently, 
however, we identified a dramatic decline in LV function 
and markedly enlarged LV volumes in naïve male NZO 
mice on normal chow at 22 weeks of age, suggesting 
a congenital and progressive heart disease of unknown 
cause in this strain.22 By state- of- the- art echocardio-
graphic imaging and histological analyses, we aimed to 
identify the pathophysiologic mechanism underlying this 
phenotype. Hereinafter, we report NZO mice as a novel 
mouse model with spontaneous development of DAVD 
and AS, resulting in a complex cardiopulmonary pheno-
type of LV failure, lung congestion, PH, and ultimately RV 
failure, that mimics the clinical presentation of patients 
with AS. Our discovery of a murine model with sponta-
neous AS development holds promise as it represents 
a novel preclinical tool to investigate mechanisms of de-
generative valve diseases and their pathophysiological 
effects on LV and RV structure and function, and to test 
for potential therapeutic interventions.
METHODS
The data that support the findings of this study are 
available from the corresponding author on reason-
able request. All animal procedures were performed 
in accordance with the Guide for the Care and Use 
of Laboratory Animals (Institute of Laboratory Animal 
Resources, 7th edition, 1996) and the European leg-
islation for animal welfare (Directive 2010/63/EU). All 
procedures were approved by the local authorities 
(G0239/16, 2347- 5- 2017) and in accordance with in-
stitutional guidelines. Detailed description of methods 
can be found in Data S1.
Animals
All mice were fed a normal rodent chow (Ssniff 
Spezialdiäten GmbH, Soest, Germany) and had iden-
tical housing conditions. Cardiovascular function was 
monitored by serial echocardiographic analysis in male 
C57BL/6J and NZO/BomHIDife (NZO) mice cohorts 
(n=10 per group) in the 6th, 12th, 18th, and 22nd week 
of age. Because the related mouse strains NZW/LacJ 
CLINICAL PERSPECTIVE
What Is New?
• Herein, we report male New Zealand obese
mice as a novel model of spontaneous degen-
erative aortic valve disease, which causes aortic
stenosis and a complex cardiopulmonary phe-
notype at early age.
• We found dysregulated matricellular protein
composition and impaired extracellular matrix
maturation as a core mechanism for the devel-
opment of degenerative aortic valve disease in
New Zealand obese mice.
What Are the Clinical Implications?
• The cardiopulmonary phenotype of New
Zealand obese mice replicates the characteris-
tic phenotype of clinical aortic stenosis, attest-
ing to the high translatability of this commercially
available model for studies of spontaneous de-
generative aortic valve disease, aortic stenosis,
and the associated cardiopulmonary end- organ
damage.
• This novel research tool paves the way for a
detailed investigation of molecular and morpho-
logical mechanisms underlying degenerative
aortic valve disease and may serve as a plat-
form for the development of novel treatment
strategies.




DAVD degenerative aortic valve disease
NZO New Zealand obese
PH pulmonary hypertension
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and NZB/BlNJ are known to display autoimmune ab-
normalities, leading to glomerulonephritis and lupus, 
we choose to investigate the cardiopulmonary pheno-
type of NZO mice compared with healthy C57BL/6J 
controls. All mice underwent weekly body weight mon-
itoring and blood glucose measurements, collected by 
tail incisions, using a Contour XT glucose meter (Bayer 
Health Care, Leverkusen, Germany). One NZO mouse 
died for unknown reasons in living week 20. After final 
echocardiography, blood samples and organs were 
collected for histopathological analyses.
Additional mice cohorts of C57BL/6J (n=30) and 
NZO (n=39) were used to perform histopathological 
analyses of the AoVs, invasive biventricular hemo-
dynamic measurements, lung ultrasound, and AoV 
echocardiography. For each individual experiment, the 
number of mice used is indicated in brackets.
Echocardiography and Image Analyses
Echocardiography of both ventricles, aorta, and lung 
was performed using a Vevo 3100 high- resolution 
Imaging System coupled to a MX400 ultra- high- 
frequency linear array transducer (18– 38 MHz; center 
transmit: 30  MHz; axial resolution: 50  μm) (both 
FUJIFILM VisualSonics, Toronto, Ontario, Canada), as 
described previously.22,23 Briefly, mice were exposed 
to 3% isoflurane (Baxter International, Deerfield, IL) and 
fixed in a dorsal position on a heating pad to maintain 
physiological body temperatures.
Assessment of AoVs and 3- dimensional echocar-
diography of the aortic arch were performed using the 
MX700 ultra- high- frequency linear array transducer 
(30– 70 MHz; center transmit: 50 MHz; axial resolution: 
30  μm; FUJIFILM VisualSonics). The 3- dimensional 
image acquisition was realized with a specialized 
3- dimensional motor (FUJIFILM VisualSonics), allow-
ing for automated stepwise movement of the probe,
as described previously by us.22 All acquired images
were digitally stored in raw format (DICOM) for further
offline analyses. Image analyses were performed by a
trained expert in small animal echocardiography using
the dedicated software package VevoLAB Version
3.1.0 (FUJIFILM VisualSonics).
Hemodynamic Assessment of Pressure 
Profiles
LV and RV pressure profiles were recorded by invasive 
hemodynamic monitoring. In brief, animals were anaes-
thetized by intraperitoneal injection of ketamine (120 µg/g 
body weight) and xylazine (16 µg/g body weight), and an-
esthetic depth was regularly monitored by checking the 
toe pinch reflex. The external jugular vein and common 
carotid artery were exposed, and a 1F microtip pres-
sure catheter (Millar, Houston, TX) was sequentially intro-
duced into each vessel and advanced into the respective 
ventricle. Stable pressure profiles were recorded for 
at least 2 minutes and analyzed by Labchart software 
(ADInstruments, Sydney, Australia). Throughout the pro-
cedure, animals were temperature controlled via a rectal 
probe and heating pad. After completion of the measure-
ments, animals were euthanized by cervical dislocation.
Histology and Histopathological Analyses
Paraffin sections of hearts and lungs (4- µm slices) were 
processed for immunohistochemistry. Whole hearts of 
neonatal pups, C57BL/6J mice, and NZO mice in the 
22nd week of age were harvested for histopathological ex-
amination of AoVs in short- axis view. Samples were fixed 
for 24 hours in 4% formalin (Thermo Scientific, Waltham, 
MA) and stored in 70% ethanol. After microdissection of 
aortic roots, tissue samples were embedded in Tissue- 
Tek OCT compound (Sakura Finetek, Alphen aan den 
Rijn, the Netherlands), frozen in 2- methylbutane (Thermo 
Scientific), cooled with dry ice, and sectioned into 6- μm 
slices. Special care was taken that AoVs were kept intact 
to ensure best quality for histological analyses. Samples 
were stained with hematoxylin and eosin to visualize ana-
tomic and morphologic structure of AoVs. Longitudinal 
cross- sections of AoVs from C57BL/6J and NZO mice 
were used for picrosirius red, Alizarin red, and Movat 
pentachrome staining. For overview images, longitudinal 
and cross- sectional heart slides and lungs were scanned 
using a MIRAX scanner (Zeiss, Ulm, Germany), which al-
lows us to obtain digitized images of whole stained organ 
sections (scale, 2 mm). Quantification of images was per-
formed using the image analysis tool from Zeiss ZEN 3.0 
(blue edition) software, calculating the tissue area in pixel² 
and the percentage of stained area from total tissue area.
Statistical Analysis
Results are shown as mean±SEM with individual scat-
ters. Statistical analyses were performed using unpaired 
Student t test, Mann- Whitney test (in which case data are 
displayed as median with interquartile range), repeated- 
measures ANOVA, or 2- way ANOVA with Bonferroni 
multiple- comparisons test as appropriate. A P<0.05 was 
assumed as statistically significant. After corroborating 
Gaussian distribution of the data by using the Shapiro- 
Wilk normality test, correlation of cardiovascular met-
rices was tested with the Pearson correlation coefficient 
(r). All analyses were performed using GraphPad Prism 
7 (GraphPad Software, La Jolla, CA).
RESULTS
Early- Onset LV Failure and Structural LV 
Remodeling in NZO Mice
On normal chow diet, NZO mice developed a pro-
nounced metabolic phenotype, characterized by 
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morbid obesity and increased serum triglyceride lev-
els at physiological blood glucose levels (Figure S1). 
Serial echocardiographic monitoring of individual an-
imals illustrates the deterioration of LV function over 
time in NZO mice (Figure 1A): when compared with 
age- matched C57BL/6J controls, NZO mice showed 
signs of LV hypertrophy, evident as increased LV wall 
thickening, LV mass, and heart- weight/tibia length 
ratios at 6 (LV mass) and 12 weeks of age (Figure 1B 
and 1C and Table 1). LV function was reduced relative 
to C57BL/6J controls, as indicated by a lower ejec-
tion fraction from 12  weeks of age onwards and a 
decrease in cardiac index after 18 weeks (Figure 1D 
and 1E). LV dilatation in NZO mice was evident as in-
creased LV end- diastolic volume at 18 and 22 weeks 
of age, whereas LV wall thickness remained un-
changed (Table  1). Because LV dilatation typically 
results from increased cardiac afterload,24 we next 
assessed relevant hemodynamic parameters of LV 
contractility, relaxation, and LV pressure profiles 
(Figure  1F and Table  2). LV pressures were found 
supraphysiological in NZO mice, with end- systolic 
pressures elevated in all measured NZO mice, and 
end- diastolic pressures showing a similar albeit less 
consistent trend, with pressures in 3 of 8 NZO mice 
markedly exceeding the highest end- diastolic pres-
sure measured in C57BL/6J controls. The notion of 
maladaptive LV remodeling was further supported by 
the results of postmortem histopathological analyses 
of cardiac cross- sections, demonstrating extensive 
thickening of the heart, an increase in total collagen 
content, and fibrotic lesions, with regions of CD68- 
positive macrophage infiltration in the LVs of NZO 
mice (Figure 1G through 1I).
DAVD in NZO Mice
To test for a valve defect in NZO mice, we imaged the 
AoVs of NZO mice and C57BL/6J controls from a par-
asternal short- axis view at the valve level with high- 
resolution echocardiography (Figure  2A). In C57BL/6J 
but also in NZO mice, we could clearly discern 3 indi-
vidual leaflets of the AoV. Yet, in comparison to the 3 
symmetrically arranged and physiologically inconspicu-
ous leaflets in C57BL/6J mice, we detected 2 severely 
thickened and a third less prominent leaflet in NZO mice. 
Consistently, postmortem histological analyses revealed 
irregularly structured, degenerative AoV in NZO mice that 
diverted markedly from the physiological morphology 
with orderly structured valvular endothelium and stroma 
in C57BL/6J AoV (Figure 2B). In all NZO mice, 1 of the 3 
valve leaflets was markedly smaller in size and dysplas-
tic or atrophic at 22 weeks of age. NZO AoVs showed 
progressive thickening with abundant valvular stroma. 
The penetrance of extensive valve thickening and ab-
normal valve morphology was found as moderate to 
severe in 83% of male NZO mice at the age of 22 weeks 
(Figure  2C). Compared with male NZO mice, female 
NZO mice presented with similar histopathological 
changes of AoV leaflets, but with decreased penetrance 
of abnormal valve morphology (13% versus 83% moder-
ate or severe, respectively; Figure S2). Compared with 
normal C57BL/6J control valves (Figure 2D), NZO mice 
showed mild endothelial hyperplasia (Figure 2E), mod-
erate extracellular or intrahistiocytic stromal thickening 
with siderocalcinosis (Figure  2F), and multifocal carti-
laginous metaplasia of the valvular stroma (Figure 2G). 
Quantitative assessment of mean valve area substan-
tiated extensive valve thickening in all examined NZO 
mice in living week 22 compared with age- matched 
C57BL/6J mice (Figure 2H). NZO mice showed mild val-
vular calcifications by Alizarin Red staining in living week 
34 (Figure S3) that was accompanied by an increase in 
proteoglycan content in Movat pentachrome (Figure 2I) 
and paralleled by decreased collagen content in picro-
sirius red staining (Figure 2J). These results indicate a 
rapidly progressing degenerative process and increased 
AoV stiffening, resulting in manifest AoV disease in NZO 
mice.
Congenital Malformation in AoVs of NZO 
Mice
Next, we aimed to investigate whether the AoV phe-
notype of adult NZO mice is caused by congenital 
malformation or develops as a consequence of rapid 
disease progression driven by environmental fac-
tors. Exemplary images from hematoxylin and eosin– 
stained AoVs of neonatal C57BL/6J and NZO mice 
demonstrate the presence of abnormal AoV thicken-
ing (black arrows) and asymmetric valve anatomy (red 
arrows) in NZO mice already shortly after birth when 
compared with C57BL/6J controls (Figure 3A), indicat-
ing congenital malformation and abnormal valvulogen-
esis as the underlying mechanism for valvular heart 
disease in NZO mice. To characterize the abnormal 
valve morphology in NZO mice in greater detail, we 
stained AoVs for periostin, a marker of valve primor-
dial differentiation and maturation.25,26 Our results indi-
cate increased periostin expression in AoVs of young 
NZO mice (3 weeks) and older NZO mice (22 weeks) 
compared with C57BL/6J controls (Figure 3B, upper 
panel), suggesting that increased periostin expression 
may constitute a congenital effect rather than a sign of 
disease progression. In contrast, we found SRY- Box 
Transcription Factor 9 (Sox9), a marker of cartilage for-
mation that is expressed during heart valve develop-
ment,27,28 to be increased as a function of age in NZO 
mice (Figure 3B, bottom panel). These results indicate 
that AoV disease in adult NZO mice is initially caused 
by congenital malformation and subsequently pro-
gresses further with age.
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DAVD Is Associated With AS, 
Regurgitation, and Dilatation
Consistent with the notion that pathologic valve 
morphology causes turbulent blood flow, which 
may result in structural and functional abnormali-
ties of the thoracic aorta,29 pulsed- wave– Doppler 
cine loops of the ascending aorta revealed peak 
velocities >3 m/s in 30% to 60% of NZO mice (de-
pending on time point), starting at the 12th week 
of age, a finding that is indicative of moderate- 
to- high grade AS (Figure  4A through 4C). Aortic 
regurgitation (AR), evident as holodiastolic flow re-
versal, was observed in both the ascending and 
Figure 1. Onset and progression of left ventricular (LV) failure in New Zealand obese (NZO) mice.
A, Representative serial echocardiographic B- and M- mode images of the LV, originating from the same animal over time. B through F, 
Echocardiographic assessed LV mass (LVM; B), heart weight/tibia length (HW/TL) ratio (C), LV ejection fraction (EF; D), and LV cardiac 
index (E) from C57BL/6J (BL6) and NZO cohorts. In addition, LV end- diastolic pressure (LVEDP; F) and LV end- systolic pressure (LVESP; 
F) were assessed by microtip catheters (presented as median±interquartile range). G, Exemplary hematoxylin and eosin (H&E)– and
picrosirius (PS) red– stained cardiac cross- sections from age- matched cohorts. H, Cardiac regions showing cell infiltration (upper
panel), fibrotic areas (middle panel), and presence of CD68+- cell (lower panel). I, Quantitative analyses of cardiac cross- sectional area
and PS- stained total collagen content in age- matched animal cohorts. Total numbers are indicated in parentheses. Data are presented 
as mean±SEM. *P<0.05 vs age- matched BL6 controls, #P<0.05 vs baseline measurement at the age of 6 weeks (wks).
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descending aorta and quantified as amount of 
backwards flowing blood (toward the left heart) per 
minute (Figure  4A, right panel, 3- dimensional). In 
line with a high prevalence of AS in NZO mice, 75% 
of NZO showed significant AR at the 22nd week 
of age, defined as flow reversal >5  mL/min. The 
degree of AS correlated with key parameters of 
echocardiographic- assessed LV function, in line 
with a physiologic link between aortic flow profiles 
and LV outcome (Figure  4E). In accordance with 
the European Association of Echocardiography/
American Society of Echocardiography recommen-
dations, aortic peak velocity was used for simplified 
classification of AS severity.30 Functional sever-
ity of AS was heterogeneous among NZO mice. 
Accordingly, 41% of NZO mice showed no signs of 
hemodynamic relevant AS, whereas 6% had AS I, 
24% had AS II, and 29% presented with AS grade 
III (Figure 4F). When stratifying hemodynamic data 
from NZO mice, which received echocardiographic 
and hemodynamic examination for AS severity, 
mice with moderate or severe AS displayed signifi-
cantly higher LV end- diastolic pressures compared 
with NZO mice with no or mild AS, demonstrating 
increased LV afterload in moderate and severe AS 
(Figure 4G). Over time, DAVD was also associated 
with altered aortic morphology: serial 2- dimensional 
monitoring of the thoracic aorta revealed a dilata-
tion of the ascending aorta, whereas other parts 
of the aortic arch remained unchanged over time 
(Figure 4H, data not shown). Aortic dilatation was 
further confirmed by novel multidimensional echo-
cardiography, which revealed increased aortic vol-
umes in NZO mice compared with C57BL/6J mice 
(Figure  4I and Videos S1 and S2). Overall, these 
data identified hemodynamic relevant AS, regurgi-
tation, and ascending aortic dilatation subsequent 
to DAVDs in NZO mice.
LV Failure Is Associated With PH and 
Ultimately RV Failure
Because secondary PH and RV failure have 
been linked to AS and left- sided valve disease, 
we next analyzed RV function in NZO mice.31 
Echocardiographic RV mass in NZO mice exceeded 
RV mass in C57BL/6J mice at all time points 
(Figure 5A), whereas the ratio of RV mass/LV mass 
remained unchanged (Figure  S4A). Concomitantly, 
RV inner diameter increased over time in NZO yet 
not in C57BL/6J mice (Figure 5B) and notably more 
so than LV inner diameter (Table 1 and Figure S4B). 
These findings suggest that dilated cardiomyopathy 
progresses faster in the RV compared with the LV, 
a result that is in line with clinical studies that iden-
tified RV failure as independent prognostic value 
for adverse outcome in LV disease.32 Increased RV 
afterload and impaired RV function were further 
substantiated by echocardiographic and postmor-
tem analyses, showing reduced tricuspid annular 
plane systolic excursion, RV ejection fraction, pul-
monary artery acceleration and ejection times, and 
an increased RV weight/tibia length ratio (Figure 5C 
through 5F and Table  3). Invasive hemodynamic 
measurements of RV systolic pressure identified 
markedly elevated RV systolic pressure values 
>30 mm Hg in 6 of 8 tested NZO mice (Figure 5G
and Table  2). Of note, 2 NZO mice had to be ex-
cluded from RV systolic pressure measurements
because of excessive congestion of the external
jugular vein, preventing proper catheter insertion.
Finally, RV function, assessed as RV ejection frac-
tion and tricuspid annular plane systolic excursion,
correlated inversely with the degree of aortic regur-
gitation and AS, suggesting AoV degeneration as
important driver of PH in NZO mice (Figure 5H).
Lung Congestion and Vascular 
Remodeling
In addition to the effects on pulmonary and RV hemo-
dynamics, we tested for echocardiographic signs of 
lung congestion in NZO mice. Starting in living week 
18 (ie, the earliest time point associated with RV dys-
function), B- lines, pleural thickening, and reduced lung 
sliding could be detected as characteristic symptoms 
Table 2. Hemodynamics in C57BL/6J and NZO Mice at 
22 Weeks of Age
Variable C57BL/6J mice NZO mice
Total No. 7 8
LV hemodynamics
LVESP, mm Hg 92.9±4.8 155.8±6.6*
LVEDP, mm Hg 6.1±0.1 10.1±2.1
dP/dtmax, mm Hg/s 8769±1078 9929±449
dP/dtmin, mm Hg/s −8743±1372 −10 376±753
τ, ms 7.4±0.5 9.8±1.9
Total No. 5 8
RV hemodynamics
RVSP, mm Hg 21.5±0.6 36.2±1.7*
RVEDP, mm Hg 0.8±1.7 5.7±0.8*
dP/dtmax, mm Hg/s 1588±294 2670±251*
dP/dtmin, mm Hg/s −918±100 −2738±389*
τ, ms 16.0±5.4 10.8±1.9
Data are represented as mean±SEM. dP/dtmax indicates maximum rate 
of pressure change; dP/dtmin, minimum rate of pressure change; LV, left 
ventricular; LVEDP, LV end- diastolic pressure; LVESP, LV end- systolic 
pressure; NZO, New Zealand obese; RV, right ventricular; RVEDP, RV end- 
diastolic pressure; RVSP, RV systolic pressure; and τ, time constant of active 
relaxation.
*P<0.05 vs C57BL/6J control group.
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of lung congestion33 in most NZO mice (Figure 6A and 
Videos S3 and S4), resulting in a marked elevation of 
the mouse lung ultrasound score for lung congestion in 
NZO mice compared with C57BL/6J mice. Finally, we 
tested whether lung congestion in NZO mice caused 
reactive lung vascular remodeling as indicator for the 
progression from isolated postcapillary PH to combined 
postcapillary and precapillary PH.34 Compared with 
C57BL/6J controls, NZO mice had normal (20– 50 µm 
vessels) or even slightly reduced mean medial wall thick-
ness (50– 150 µm vessels), and muscularization of small 
pulmonary microvessels did not differ between NZO 
and C57BL/6J mice (Figure 6B through 6D). That not-
withstanding, lung fibrosis was evident as an increase in 
picrosirius red– stained total collagen I and III in lungs of 
NZO compared with C57BL/6J mice (Figure 6E).
Figure 2. Siderocalcinosis and multifocal cartilaginous metaplasia in aortic valves (AoVs) of New Zealand obese (NZO) 
mice.
A, Schematic overview of a parasternal short- axis view at the aortic valve level and corresponding high- resolution echocardiographic 
B- mode images of AoVs in NZO and age- matched C57BL/6J (BL6) mice. White arrows indicate leaflets. B, Hematoxylin and eosin– 
stained cross- sections of AoVs in a short- axis view at 2.5- fold magnification. C, Semiquantitative analyses of AoV thickening and
abnormal valve morphology in age- matched BL6 and NZO mice (both 22 weeks). D, The ×20 magnification indicated physiologic aortic 
valve morphology in BL6 mice compared with pathophysiological endothelial hyperplasia (E), stromal thickening with siderocalcinosis 
(F), and multifocal cartilaginous metaplasia (G) in age- matched NZO mice. H, Quantification of AoV mean area in BL6 and NZO mice
at 22 weeks of age. I, Longitudinal cross- sections of the aortic valve stained with Movat pentachrome stain (MPS) and (J) picrosirius
(PS) red with corresponding quantitative analyses of proteoglycans (stained blue, MPS) and collagen content (stained red [SR]),
respectively. Total numbers are indicated in parentheses. Data are presented as mean±SEM. LA indicates left atrium; LC, left coronary 
leaflet; NC, noncoronary leaflet; PA, pulmonary artery; PV, pulmonary valve; RA, right atrium; RC, right coronary leaflet; RVOT, right
ventricular outflow tract; TV, tricuspid valve; and wks, weeks. *P<0.05 vs age- matched BL6 controls.
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DISCUSSION
Collectively, our results demonstrate a complex car-
diopulmonary phenotype in male naïve NZO mice 
that originates from a progressive degeneration of the 
AoVs. In contrast to previously reported murine models 
of AS, which rely on surgical interventions or complex 
induction of multiple risk factors for manifest AS de-
velopment,15,16,18 NZO mice develop spontaneous AS 
and may thus present a clinically relevant and versatile 
model for pathomechanistic and therapeutic studies of 
AS. The translatability of this naturally and intrinsically 
occurring cardiopulmonary phenotype is highlighted by 
the facts that NZO mice (1) carry several clinical risk fac-
tors for AS (namely, obesity and dyslipidemia), which 
likely trigger or promote the multifactorial disease20,21 
and (2) replicate the characteristic cardiopulmonary 
phenotype of clinical AS, with aortic regurgitation, LV 
Figure 3. Congenital malformation as the underlying cause of aortic stenosis in New Zealand obese (NZO) mice.
A, Exemplary images of hematoxylin and eosin– stained aortic valves from neonatal C57BL/6J (BL6) and NZO mice (<3 days after 
birth), indicating aortic valve thickening (black arrows) and asymmetric leaflet formation (red arrows) in NZO mice compared with BL6 
controls. B, Exemplary images of immunofluorescence staining and corresponding quantitative analyses of periostin (upper panel) 
and Sox9 (lower panel) in male BL6 mice (22 weeks) and NZO mice (3 and 22 weeks). Total numbers are indicated in parentheses. Data 
are presented as mean±SEM. *P<0.05 vs BL6 controls.
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hypertrophy progressing to decompensated LV failure, 
PH, and ultimately RV dilation and failure.
In humans, DAVD is the most common cause of 
AS and considered as an active, proliferative, and 
progressive disease, that is accelerated by multiple 
risk factors similar to those associated with atheroscle-
rotic disease.35– 37 Risk factor modifications via drug 
treatment and lifestyle intervention can reduce the 
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incidence of AS and slow down the progressive nature 
of the disease process.13 AS ranges from a relatively 
benign course in asymptomatic patients to a disease 
with high mortality rate once symptoms develop.38 Of 
interest, this physiological continuum is equally evident 
in male NZO mice of genetically identical ancestry, in 
that 50% of mice present with moderate or severe AS 
and AR, whereas the other half only shows mild AS or 
no phenotype at all. Notably, this heterogeneity in AS 
severity directly translates into diastolic LV function in 
that mice with more severe AS show increased LV end- 
diastolic pressure values compared with littermates 
with no or mild AS. Our findings in NZO mice thus rep-
licate the situation in patients, where the initial pace 
of the disease process may differ between individuals, 
yet hemodynamic changes occur rapidly and uniformly 
once AoV obstruction develops.39,40 Moreover, some 
NZO mice displayed ventricular failure in the absence 
of AS, suggesting a role for hemodynamically indepen-
dent factors to the cardiopulmonary phenotype of NZO 
mice, as described for AS pathogenesis.41,42 Although 
some female mice developed abnormal AoVs with ex-
tensive thickening of valvular leaflets and reduced col-
lagen content, similar to their male counterparts, overall 
penetrance of this phenotype was markedly lower in 
females than in males. These findings are in line with 
clinical data, as women are less often diagnosed with 
AS43 and the corresponding fibrocalcific changes of 
aortic leaflets than men,3 although, paradoxically, they 
tend to have a worse outcome.44 The observed sex 
differences are further in line with our previous findings 
demonstrating that female, as opposed to male, NZO 
mice are protected from mitochondrial dysfunction and 
impaired cardiac energy metabolism.45
According to the clinical guidelines, echocardiog-
raphy is the key diagnostic modality to confirm the 
presence and severity of AS and to assess the degree 
of ventricular dysfunction in patients.2 The echocar-
diographic phenotype of NZO mice matches the clin-
ical presentation of patients with AS, as illustrated by 
increased peak velocities in the ascending aorta, AR 
with holodiastolic flow reversal, and dilatation of the 
ascending aorta, a common complication in patients 
with calcific AS.46
AS in NZO mice was not attributable to a bicus-
pid AoV, yet, AoVs displayed an asymmetric valve 
anatomy shortly after birth, a finding that is strongly 
associated with the future development of AS in pa-
tients.47 Similarly, histopathological evidence for en-
dothelial injury, cartilaginous transformation, periostin 
overexpression, and valvular thickening in NZO mice 
is closely reminiscent to similar findings in human AS, 
where these pathological features are considered to 
cause stiffening of the AoVs before the deposition of 
collagen and calcium.48,49 NZO mice showed a pattern 
of increased proteoglycan and decreased collagen 
expression, indicating drastic remodeling of the val-
vular extracellular matrix.50 In the steady state, AoVs 
are composed of 3 extracellular matrix layers: (1) col-
lagens (fibrosa), (2) proteoglycans (spongiosa), and (3) 
and elastin (ventricularis). In calcific AS, proteoglycans 
typically become overexpressed, actively participating 
in lipid retention and modification.51 An association 
between proteoglycan overexpression and calcified 
regions has also been found in human DAVD, as pro-
teoglycans accumulate around calcified nodules in the 
fibrosa layer.52,53 Particularly, small leucin- rich proteo-
glycans were shown to play a key role in DAVD be-
cause of their potency to interact with inflammatory 
molecules and immune cells and their capacity to pro-
mote lipid retention.54
Sox9 is known to play a key role in heart valve mat-
uration after birth by regulating extracellular matrix 
proteins.27 The finding that adult NZO mice upregulate 
Sox9 is unexpected as previous studies have mainly 
addressed the role of Sox9 during valvulogenesis,27 
yet little is known about its function in mature heart 
valves and potential functional consequences. Of note, 
increased Sox9 expression has been reported in mu-
rine models of myxomatous valve disease, which is the 
most common cause of mitral valve regurgitation.55,56 
In myxomatous valve disease, enhanced Sox9 ex-
pression is associated with increased proteoglycan 
composition.57 Conversely, Sox9+/− mice exhibit AoV 
Figure 4. Stromal thickening of aortic valves causes aortic regurgitation and thoracic aortopathy in New Zealand obese 
(NZO) mice.
A, Exemplary serial echocardiographic B- mode and color- Doppler images of the aortic arch, originating from the same animal (left 
panel). Pulsed- wave (PW)– Doppler– assessed velocity profiles from the ascending and descending aorta (right panel). Yellow dashed 
line was set as a landmark and indicates a velocity of 1 m/s in ascending aorta or 25 m/s in descending aorta. Red line highlights 
holodiastolic flow reversal. B through D, Quantification of turbulent flow, peak velocity profiles, and aortic regurgitation from PW- 
Doppler cine loops of the ascending aorta. E, Correlation analyses of left ventricular (LV) end- systolic volume (ESV), LV end- diastolic 
volume (EDV), and ejection fraction (EF) with the degree of aortic stenosis expressed as ascending aortic peak velocity in age- matched 
mice cohorts. F, Aortic stenosis (AS) severity graded according to the ascending peak velocity profile (≤2500 mm/s=no AS, 2500– 
3000 mm/s=AS I, 3000– 4000 mm/s=AS II, and ≥4000 mm/s=AS III). G, LV end- diastolic pressure (LVEDP) of NZO mice, stratified by AS 
severity. H, Dilatation of the ascending aorta, defined as the ascending aortic diameter/LV outflow tract ratio. Analysis was based on 
2- dimensional B- mode images of the aortic arch. I, Three- dimensional reconstruction of traced multidimensional echocardiographic
B- mode images from the ascending aorta and related quantification of ascending aortic volumes. Total numbers are indicated in
parentheses. Data are presented as mean±SEM. AR indicates aortic regurgitation; and wks, weeks. *P<0.05 vs age- matched C57BL/6J 
(BL6) controls.
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calcification associated with reduced proteoglycan ex-
pression.58 Proper proteoglycan expression is crucial 
for the regular function and integrity of mature valvu-
lar leaflets,59 highlighting an important role for Sox9 in 
maintaining physiologic valvular tissue composition. 
Sox9 dysregulation in NZO mice may therefore have 
profound effects by promoting proteoglycan- related 
valvular heart disease associated with valve stiffening.
Figure 5. Pulmonary hypertension and right ventricular (RV) failure in New Zealand obese (NZO) mice.
RV mass (RVM) (A) and RV internal diameter (RVID) (B), as assessed via echocardiography, tricuspid annular plane systolic excursion 
(TAPSE) (C) and RV ejection fraction (EF) (D) in C57BL/6J (BL6) and NZO mice of 22 weeks of age, and representative echocardiographic 
images (E) show pulsed- wave– Doppler flow profiles of the tricuspid valve derived from a 4- chamber view (upper panel), TAPSE, 
originating from a 4- chamber view (upper mid), M- modes of the RV in parasternal long- axis view (lower mid), and a flow profile of the 
pulmonary artery assessed from a parasternal short- axis view on the valve level (bottom panel) in BL6 and NZO mice of 22 weeks of 
age. RV weight/tibia length (TL) (F) and RV systolic pressure (RVSP) (G), as measured by RV catheterization in BL6 and NZO mice. H, 
Correlation analyses of RV function to the degree of aortic stenosis and regurgitation. Total numbers are indicated in parentheses. 
Data are presented as mean±SEM. *P<0.05 vs age- matched BL6 controls, #P<0.05 vs baseline measurement at sixth week of age.
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In contrast to increased Sox9 expression, elevated 
periostin expression is already present in young NZO 
mice and may indicate a congenital defect and early 
disease manifestation rather than a disease progres-
sion. Periostin regulates collagen fibrillogenesis,60 and 
its overexpression results in increased matrix com-
paction,61 highlighting periostin as a mediator of ma-
trix remodeling toward a mature valve structure during 
valvulogenesis. In line with this concept, data from his-
topathological findings in human AoVs show periostin 
expression to be strikingly upregulated and expanded 
in adult patients with atherosclerotic and rheumatic 
valvular heart disease.62 Altogether, impaired Sox9, 
periostin, and proteoglycan expression patterns point 
toward dysregulated protein composition and impaired 
extracellular matrix maturation in NZO mice compared 
with C57BL/6J controls, which might be a core mech-
anism for the development of AS in NZO mice.
Clinically, AS and the subsequent emergence of aor-
tic regurgitation trigger the hemodynamic propagation 
of the disease process via increased LV pressure and 
volume, resulting in the development of left- sided val-
vular heart disease. The characteristic features of this 
process, such as increased myocardial cell mass, in-
terstitial fibrosis, and echocardiographic evidence of LV 
failure, are equally evident in NZO mice.46 As LV failure 
progresses, LV diastolic function declines, as evident 
by LV end- diastolic dilatation and increase in τ, result-
ing in increased LV preload (LV end- diastolic pressure) 
and congestive heart failure with progressive transmis-
sion of elevated hemodynamic pressures from the LV 
to the left atrium and into the lung, where congestive 
pulmonary edema can be detected by lung ultrasound. 
In some clinical cases, the pulmonary vasculature 
adapts to these elevated hemodynamic pressures by 
extensive remodeling of the vascular intima, media, 
and perivascular interstitium, thus further aggravating 
right- sided heart afterload via a combination of pre-
capillary and postcapillary PH.63 Ultimately, postcap-
illary PH or combined precapillary and postcapillary 
PH result in progressive RV dilatation and failure, as 
demonstrated by the progressive increase in RV inner 
diameter and reduced RV ejection fraction. Although 
this pathophysiological sequence is well established in 
humans and recapitulated in rat or guinea pig mod-
els of aortic banding,64,65 similar models in mice pro-
duced a less pronounced pulmonary phenotype with 
moderate pulmonary vascular remodeling.66 The find-
ings in NZO mice are in line with these reports in that 
there was a similar trend for increased small pulmo-
nary artery muscularization compared with C57BL/6J 
mice, which, however, failed to reach the level of sig-
nificance. That notwithstanding, NZO mice present, to 
our knowledge, the first murine model of spontaneous 
PH with left- sided heart disease and metabolic syn-
drome, mimicking another highly prevalent yet poorly 
understood clinical scenario.67
Although we provide, to our knowledge, the most 
extensive echocardiographic assessment of DAVD, 
AS, and associated end- organ damages in a murine 
model to date, our data set is at the same time re-
stricted to the technical limitations of small animal 
echocardiography. This notion refers specifically to the 
calculation of AoV area using the continuity equation, 
which is the standard of care for the assessment of AS 
severity in humans.2,30 AoV area calculations become 
important when aortic velocity profiles are higher than 
normal (eg, coexisting AR) or lower than normal (eg, 
LV dysfunction) as transaortic velocities and gradients 
vary with volumes.46 Unfortunately, AoV area measure-
ments/calculations are presently not feasible in mice 
because of the deficiency of continuous- wave Doppler 
ultrasound technique in small animal ultrasound de-
vices, a technique that is highly recommended for the 
precise assessment of valve stenosis in clinical prac-
tice.30 As a result, diagnosis of AS in murine models is 
Table 3. Echocardiographic Parameters of RV Function at 
22 Weeks of Age
Variable C57BL/6J mice NZO mice
Total No. 10 9
RV dimension
RVID, d, mm 1.45±0.02 1.99±0.04*
RVAW, d, mm 0.39±0.01 (9) 0.44±0.02*
RVID/LVID 0.33±0.01 0.42±0.01*
RV function







E/A ratio 0.65±0.03 (8) 0.52±0.05* (8)
RIMP 0.36±0.03 (8) 0.57±0.04* (6)
TAPSE, mm 1.23±0.04 0.86±0.05*
EF, % 64.6±2.0 (9) 50.2±3.6
PV measurements
PAT, ms 24.4±1.04 20.4±0.7*
PET, ms 92.5±2.5 76.6±3.3*




PA VTI, mm 31.4±1.4 26.9±2.0
Numbers in parentheses indicate numbers of analyzed images, when 
different from animal number. Total numbers may diverge because of 
occasionally poor image quality. Data are represented as mean±SEM. A 
indicates late diastolic filling; E, peak early filling; EF, ejection fraction; IVCT, 
isovolumetric contractility time; LVID, left ventricular inner diameter; NZO, 
New Zealand obese; PA VTI, pulmonary artery velocity time integral; PAT, 
pulmonary acceleration time; PET, pulmonary ejection time; PV, pulmonary 
vascular; RIMP, RV index of myocardial performance; RV, right ventricular; 
RVAW, d, diastolic RV anterior wall; RVID, d, diastolic RV inner diameter; and 
TAPSE, tricuspid annular plane systolic excursion.
*P<0.05 vs C57BL/6J control group.
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presently restricted to the measurement of aortic ve-
locity profiles, which may lead to false- negative results. 
Notably, in the present study, this might have led to an 
underestimation of AS incidence and severity in NZO 
mice.
CONCLUSIONS
Herein, we report, to our knowledge, a novel murine 
model that spontaneously develops DAVD and AS at 
an early age. The resulting complex cardiopulmonary 
Figure 6. Lung congestion and fibrosis in New Zealand obese (NZO) mice.
A, Exemplary lung ultrasound images of the right lung from C57BL/6J (BL6) and NZO mice at different ages with corresponding 
semiquantitative mouse lung ultrasound (MoLUS) scores indicating congestive pulmonary edema in NZO compared with BL6 mice. 
Arrows indicate emerging B- lines, and asterisks indicate pleural thickening. B, Representative images of hematoxylin and eosin 
(H&E)– stained (upper panel), α- smooth muscle actin (α- SMA)– stained (middle panel), and picrosirius (PS) red– stained (lower panel) 
lung vessels stratified by vessel diameters ranging from 20 to 50 and 50 to 150 µm. C, Corresponding quantification of vascular wall 
thickness relative to vessel diameter (=medial wall thickness) in H&E- stained lung microvessels of 20 to 50 and 50 to 150 µm diameter. 
Semiquantitative analysis of none, partially, and fully muscularized α- SMA– stained lung microvessels (20– 50 µm diameter) (D) and 
quantitative analysis of PS- stained lung sections (E), indicating the fraction of total collagen positive area over total lung tissue. Total 
numbers are indicated in parentheses. Data are presented as mean±SEM. *P<0.05 vs age- matched BL6 controls.
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phenotype in NZO mice closely mimics the corre-
sponding clinical scenario in patients, attesting to 
the high translatability of this commercially available 
model for studies of DAVD and AS as well as the asso-
ciated cardiopulmonary end- organ damage. This new 
research tool paves the way for the detailed investi-
gation of molecular and morphological mechanisms 
underlying AS and may serve as a platform for the 
testing of novel drug targets and treatment strategies.
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Supplemental Methods and Results 
Echocardiography 
Echocardiography of both ventricles, the aorta, and the lung was performed using a 
Vevo® 3100 high-resolution Imaging System coupled to a MX400 ultra-high frequency 
linear array transducer (18-38 MHz, center transmit: 30 MHz, axial resolution: 50 μm) 
(both FUJIFILM VisualSonics, Toronto, Ontario, Canada) as described previously22,23. 
Briefly, mice were exposed to 3% isoflurane (Baxter International, Deerfield, USA) and 
fixed in a dorsal position on a heating pad to maintain physiological body temperatures. 
During echocardiographic examination, mice were continuously monitored by ECG 
recording. The anterior thorax was depilated to optimize the acoustic interface. Pre-
warmed ultrasound gel (Parker Laboratories Fairfield, New Jersey, USA) was applied 
on the chest for echocardiographic image acquisition of B- and M-Mode images of both 
ventricles and the aorta. Velocity profiles of the aorta, the pulmonary valve outflow 
(parasternal short axis view at the level of the AoV), and the tricuspid valve (four-
chamber view) were assessed using color and pulse wave (PW) Doppler 
echocardiography. Lung ultrasound (LUS) was performed over the right-side 
pulmonary field identified by the clearly visible pleural line and pleural space in a 
parasternal long axis view. 
Assessment of AoVs and three-dimensional (3D) echocardiography of the aortic arch 
were performed using the MX700 ultra-high frequency linear array transducer (30-70 
MHz, center transmit: 50 MHz, axial resolution: 30 μm; FUJIFILM VisualSonics). 3D 
image acquisition was realized with a specialized 3D-motor (FUJIFILM VisualSonics), 
allowing for automated stepwise movement of the probe, as described by us 
previously22. To this end, a B-mode image obtained at the maximum dimension of the 
aortic arch served as starting point for consecutive image recordings (3D range: 3.5–
4 mm (depending on the size of the aortic arch), frequency: 50 MHz, step size: 50 μm). 
AoVs were recorded in a parasternal short axis view at the level of the AoV using ECG-
gated kilohertz visualization (EKV, 1000 Hz), allowing increased temporo-spatial 
resolution by averaging multiple cardiac cycles. All acquired images were digitally 
stored in raw format (DICOM) for further offline analyses. 
Echocardiographic Image Analyses 
Image analyses were performed by a trained expert in small animal echocardiography 
using the dedicated software package VevoLAB Version 3.1.0 (FUJIFILM 
VisualSonics) LV dimensions, RV dimensions and RV function were calculated from 
acquired M-Mode images in a parasternal long axis view. A minimum of two 
independent M-Mode images and 3 consecutive cardiac cycles, respectively, was 
analyzed, resulting in n>6 subsequently averaged values per individual animal. Global 
LV systolic function and heart rate were assessed from two independent B-Mode 
images derived from parasternal long axis views. Calculation of LV function was based 
on endocardial border tracing from LV outflow tract to apex using the monoplane 
Simpson’s method of discs. For calculation of cardiac index, we extrapolated body 
surface area from body weights by a species-specific formula for mice68 and matched 
it to cardiac output values assessed on the same day in the same animal. Doppler 
signals were analyzed over a minimum of five cardiac cycles per individual animal and 
measurements were subsequently averaged. In line with the clinical scenario, we 
classified AS severity by using the ascending aortic peak velocity profiles of B6 and 
NZO mice30. AS grades were defined as followed: no AS≤2500mm/s (no hemodynamic 
relevant AS), AS I=2500-3000mm/s (mild), AS II=3000-4000mm/s (moderate) and AS 
III≥4000mm/s (severe). Pulmonary artery measurements and calculation of the RV 
index of myocardial performance (RIMP) were carried out as described previously69. 
Stored LUS cine loops were scored according to the mouse lung ultrasound score 
(MoLUS), considering lung sliding during respiration, predominant line profile, 
echography color and pleural abnormalities70. 3D cine loops of the aorta were loaded 
into the 4D-analyses tool of VevoLab. The maximum dimension of the aortic arch was 
identified by browsing through the cubical view of the cine loop. The contour of the 
aortic arch was traced by starting 0.3 mm inward of the brachiocephalic artery. A total 
of 40 contours with a step size of 0.1 mm (yielding a total tracing distance of 4 mm) 
were drawn. To evaluate a completed tracing, the 3D reconstruction was reviewed by 
a second observer to exclude tracing irregularities.  
IHC staining (H&E, PS) 
All slides underwent deparaffinization and subsequent rehydration via a decreasing 
ethanol series. For H&E staining, slides were placed in Haemalaun solution (Carl Roth, 
Karlsruhe, Germany) for 3 min, followed by tap water washing for 10 min and 30 s of 
dH2O. Next, 1% aqueous eosin solution (Eosin Y, Fluka 45240) was added for 1 min 
followed by another washing step. Picrosirius (PS) red staining was carried out using 
Sirius Red solution (0.5g Direct red 80 (365548, Sigma-Aldrich) in 500 ml saturated 
picric acid (Morphisto 10339) for 1 h at RT. Afterwards, slides were washed twice in 
0.5 % acetic acid for only few seconds and excess dye was washed out. After H&E 
and PS staining, slides were dehydrated and mounted with Histofluid (6900002, 
Engelbrecht, Germany).   
Histology- IHC staining AoVs (H&E, PS, Alizarin Red, Movat’s stain) 
Whole hearts of BL6 mice in the 22nd week of age and of NZO mice in the 12th (n=3) 
and 22nd (n=4) week of age were harvested for histopathological investigation of AoVs 
in short axis view. Samples were fixed for 24 h in 4 % Formalin (Thermo Scientific, 
Waltham, USA) and then stored in 70% ethanol. After microdissection of aortic roots, 
tissue samples were embedded in Tissue-Tek OCT compound (Sakura Finetek, 
Alphen aan den Rijn, The Netherlands), frozen in 2-methylbutane (Thermo Scientific) 
cooled with dry ice and sectioned into 6-μm slices. Special care was taken that aortic 
valves were kept intact to ensure best quality of the histological analyses. Samples 
were stained with H&E (mentioned above) to visualize the anatomic and morphologic 
structure of aortic valves. Longitudinal cross-sections of AoVs from BL6 and NZO mice 
were used for PS (see above), Alizarin Red and Movat’s stain.  
For Alizarin Red staining, paraformaldehyde-fixed AoVs were deparaffinized and 
rehydrated to dH2O. Slides were stained with Alizarin Red Solution (2 g Alizarin Red S 
(K844, Fluka, Germany)) solved in 100 ml dH2O, pH adjusted to 4.1~4.3 using 10 % 
ammonium hydroxide) for 2.5 min. Excess dye was washed out and samples 
dehydrated in acetone (20 s) followed by Acetone-Xylene (1:1) solution (20 s). Finally, 
samples were cleared in xylene and mounted with Histofluid. 
For Movat`s stain deparaffinized and rehydrated slides were placed 10 min in 1% 
aqueous Alcian Blue solution (Alcian blue 8GS Chroma 1A288) followed by 5 min of 
tap water washing and 1 h incubation in alkaline ethanol (Morphisto 10132). Afterwards 
slides were washed 10 min in tap water and 1 min in dH2O. Following, slides were 
placed 10 min in Weigerts Hematoxylin (Chroma A: 2E032 + B: 2E052, Waldeck 
GmbH&Co.KG, Germany) before washed once more with tap water for 15 min. Next, 
Brilliant Crocein-Acid Fuchsine (Chroma1B109/Chroma1B525 4:1, Waldeck 
GmbH&Co.KG, Germany) was added for 15 min followed by washing the slides with 
0.5 % acetic acid. Afterwards, slides were placed 20 min in 5 % Phosphotungstic acid 
(Chroma 3D092, Waldeck GmbH&Co.KG, Germany) followed by washing with 0.5 % 
acetic acid. Next, slides were washed with 100% ethanol 3 times for 5 min, followed 
by 1h incubation with Saffron du Gatinais (Chroma 5A394, Waldeck GmbH&Co.KG, 
Germany). Afterwards slides were washed with 100% ethanol 3 times for 5 min and 
finalized by two times for 5 min toluene and permanently embedding of the sections 
with Histofluid (yellow: collagen; blue-green: proteoglycans cartilage/tissue, dark-red: 
osteoid, red: elastic fibers; black: nuclei, reddish: cytoplasm; light blue: acid 
glucosaminoglycan). 
Immunofluorescence staining AoVs (periostin and Sox9)) 
For immunofluorescence analysis of periostin and Sox9, sections were deparaffinized 
and rehydrated in Roti-Histol (Carl Roth, Karlsruhe, Germany) followed by a 
decreasing ethanol series. For heat-mediated antigen retrieval, slides were placed in 
citrate-buffer (10mM cirtrate acid, 0.05% Tween 20 in dH2O) for 20 min at 95°C in a 
water bath, followed by cooling over 15 min at RT and blocking (Antibody Diluent, 
Agilent, Waldbronn, Germany), containing 10 % goat serum for 1 h. Rabbit anti-
periostin (ab215499, abcam, Berlin, Germany, 1:500) and rabbit anti-Sox9 (#82630T, 
cell signaling, Frankfurt, Germany, 1:100) diluted in blocking solution were used as 
primary antibodies and incubated for 1 h in a lightproof humidified chamber at RT. 
Afterwards, slides were incubated with AlexaFluor 488 secondary antibody for 30 min 
(Invitrogen, Darmstadt, Germany) and mounted with FluorCare mounting medium 
containing DAPI (Carl Roth, Karlsruhe, Germany).  
Histology- IHC antibody staining: CD68 and α-SMA 
For CD68 and α-SMA, slides we deparaffinized, rehydrated and heat-mediated antigen 
retrieval and blocking was performed as above. Additionally, sections were blocked 
with 0.03 % hydrogen peroxide (Peroxidase block; Agilent) for 10 min at RT, followed 
by incubation with primary antibodies for 1 h in a lightproof humidified chamber at RT. 
Rabbit anti-CD68 antibody (ab125212, Abcam, Cambridge, UK) was used, followed by 
a 30-min incubation with horseradish peroxidase-labeled polymer. Next, tissue 
sections were incubated with substrate-chromogen solution, 3,3′-Diaminobenzidin 
(EnVision+ system-HRP (DAB), Agilent Waldbronn, Germany),  counterstained with 
hematoxylin (Sigma-Aldrich, Taufkirchen, Germany) and mounted with Entellan (Merck 
Millipore, Darmstadt, Germany). For anti-alpha smooth muscle actin (α-SMA) staining, 
lung sections were incubated with rabbit anti-α-SMA antibody (ab5694, Abcam, 
Germany) at 4°C overnight, followed by a 30 min incubation with the secondary 
antibody (414341F, rabbit anti-Histofine, Medac, Wedel, Germany) at RT (detection 
via HRP/DAB system as described above).  
Histological analyses 
For overview images, longitudinal and cross-sectional heart slides and lungs were 
scanned using a MIRAX scanner (Zeiss, Ulm, Germany), which allows to obtain 
digitized images of whole stained organ sections (scale 2000 µm, 200 µm). Histological 
staining’s of hearts and lungs were scanned and analyzed with AxioCamMRm (Zeiss, 
Oberkochen, Germany) and CaseViewer Software Version 2.3 (3DHISTECH Ltd, 
Budapest, Hungary).  
Quantitative analyses 
α-SMA lung staining 
α-SMA lung staining was analyzed in at least 50 microvessels per animal by grading 
the muscularization status as non-, partially or fully muscularized. Medial wall thickness 
was determined in H&E staining by measuring the external and internal diameter of all 
detectable 20-50 µm vessels and 50-150 µm vessels per cross section (average vessel 
number analyzed per mouse: 20-50 µm vessels = 13.9; 50-150 mm vessels = 9.8). 
Relative vessel wall thickness was calculated as (external diameter–internal 
diameter)/(external diameterx100). Absolute vessel wall thickness in µm was 
calculated as (external diameter-internal diameter)/2. 
Mean area/size of heart/valve tissue 
Quantification of mean heart/valve tissue area was performed using the image analysis 
tool of the Zeiss Zen 3.0 (blue edition) software, obtaining the area in pixel². For heart 
cross section we analyzed and compared the total area in pixel² and for valve size 
quantification we calculated the mean area of all valve leaflets per sample that could 
be detected. 
PS red-stained collagen content in heart/lung sections 
Quantification of PS red-stained collagen content in lung sections was performed using 
the image analysis tool of the Zeiss ZEN 3.0 (blue edition) software, calculating the 
percentage fraction of PS red-stained collagen fibers (total stained pixel²) relative to 
the total heart/lung area (yellow, total pixel²).  
Penetrance of aortic valve thickening phenotype 
Semi-quantitative analysis of aortic valve thickening was performed by a blinded expert 
in veterinary pathology. H&E-stained aortic valves of age-matched, male B6 and 
male/female NZO mice were graded to assess the degree of valve thickening as 
follows: 0=none, 1=mild, 2=moderate, 3=severe thickening of aortic valve leaflets, 
respectively. 
Triglyceride measurements 
Plasma triglyceride (TG) levels of BL6 and NZO mice in the 22nd week of age were 
measured by a colorimetric assay according to the manufacturer’s instructions 
(A11A01640, HORIBA Europe GmbH, Oberursel, Germany) using the ABX Pentra 400 
benchtop analyzer (Horiba, Kyoto, Japan).  
Figure S1 Metabolic Phenotype of NZO-mice. 
A Weekly monitored body weight (BW) of BL6 and NZO mice (BL6: r=0.967, 
95%CI=0.910 to 0.989, p<0.0001; NZO: r=0.968, 95%CI=0.914 to 0.989, p<0.0001). 
B Blood glucose (BG) levels of BL6 and NZO mice (BL6: r=0.242, 95%CI=-0.270 to 
0.648, p=0.349; NZO: r=0.705, 95%CI=0.339 to 0.886, p=0.002). Dashed line was set 
as landmark and indicates a BG level of 16.6 mmol/l, which was considered as 
manifest diabetes. Repeated measures ANOVA (A and B) C Triglyceride (TG) content 
measured in serum samples of BL6 and NZO mice. Data are represented as 
mean±SEM. *p<.05 vs. age-matched BL6 controls. n-numbers are indicated in 
brackets. 
Figure S2. Side-by-side comparison of the histological aortic valve phenotype in 
male and female NZO mice. 
A Exemplary images of H&E and Picrosirius Red (SR) stained aortic valves from male 
and female NZO mice (both 22 weeks). B Semi-quantitative analyses of aortic valve 
thickening and abnormal valve morphology of H&E-stained aortic valves from male 
(n=18) and female (n=15) NZO mice. 0=none, 1=mild, 2=moderate and 3=severe 
thickening of aortic valve leaflets, respectively.  
Figure S3. Alizarin red staining of aortic valves in NZO mice. 
The exemplary images show mild calcific aortic valve disease in a male NZO mouse 
at the age of 34 weeks (right). Parts of the positive signal in Alizarin Red staining might 
be caused by melanocytes, as indicated by including a unstained control section from 
the same animal (left). 
Figure S4. RV/LV dynamics. 
A Right ventricular (RV) internal diameter-to-left ventricular (LV) internal diameter-ratio 
(RVID/LVID) and B RV mass-to-LV mass-ratio (RVM/LVM) as assessed via 
echocardiography. Data are represented as mean±SEM *p<.05 vs. age matched BL6 
controls, #p<.05 vs. baseline measurement at 6th week of age, n-numbers are 
indicated in brackets. 
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Supplemental Video Legends: 
Video S1. Exemplary 3D reconstruction of aortic arch of BL6 control mouse. 
Best viewed with Windows Media Player. 
Video S2. Exemplary 3D reconstruction of aortic arch of NZO mouse. Best 
viewed with Windows Media Player. 
Video S3. Exemplary lung ultrasound cine loop of BL6 control mouse. Best 
viewed with Windows Media Player. 
Video S4. Exemplary lung ultrasound cine loop of NZO mouse. Best viewed with 
Windows Media Player. 
